Condition Directory

Hypertension clinical trials

Directory of U.S. ClinicalTrials.gov public records for Hypertension. Browse Hypertension recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3919

Shown on this page

Current sort

How Hypertension studies are organized in the registry

“Hypertension” searches also surface pulmonary hypertension — a different disease with its own research community — so watch for “pulmonary” in titles when scanning results. The blood-pressure portfolio itself includes a high share of behavioral, dietary, and device studies alongside medication trials.

Terms that often appear in related listings

blood pressure resistant hypertension pulmonary hypertension renal denervation

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1117–1128 of 3,919 matching trials for Hypertension.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: Goode Health Beverage, Vanilla Base Beverage Blend; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Arlington, Texas

Conditions: Cardiovascular Diseases, Hypertension, Diet
Interventions: Energy Drink, Water Control; Dietary Supplement · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 30 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions: Peanut group; Dietary Supplement
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: JNJ-67896049; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Anderson, South Carolina • Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: PAH
Interventions: oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Bosentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 3
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • New York, New York

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Prostacyclin Receptor Agonist; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan, Tadalafil, Selexipag; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 20
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more

About this Hypertension clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Hypertension as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Hypertension.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Hypertension clinical trials

How Hypertension studies are organized in the registry

Filter and sort this condition

Live official records

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

The Impact of Goode Health Beverage on Markers of Physiological and Neurocognitive Health

The Acute Effect of and Energy Drink vs. Water Consumption on MAP, HR, and Energy Metabolism

Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals

A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

FUTURE 3 Study Extension

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

About this Hypertension clinical trials directory page